Express Scripts sees no let-up in drug pricing chatter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Mizuho Securities Remains Sidelined on Express Scripts (ESRX) Following 2017 Guidance
December 14, 2016 1:16 PM ESTMizuho Securities reiterated a Neutral rating and $76.00 price target on Express Scripts (NASDAQ: ESRX) following the company's initial 2017 guidance. 2017 adjusted EPS guidance is $6.82-$7.02, relatively in-line with consensus of $6.93 at the midpoint ($6.92), implies a +7-10% adjusted EPS growth y/y.
Analyst Ann Hynes commented,... More
